Medicare 2026: What to know about premiums, Part D, impact from government shutdown

Medicare's 2026 open enrollment period introduces mixed changes, with average monthly premiums for Medicare Advantage plans with prescription drug coverage projected to decrease from $16 to $14, and stand-alone Part D premiums dropping from $38 to $34. However, the number of stand-alone Part D plans will decline, and some Medicare Advantage providers are reducing service areas, while insurers gain flexibility to raise Part D premiums up to $50 monthly. CMS drug price negotiations are expected to yield significant discounts on key medications, potentially impacting pharmaceutical revenues, though the annual out-of-pocket cap for Part D drugs will increase to $2,100, suggesting a complex financial landscape for beneficiaries and industry stakeholders.

Analysis

The 2026 Medicare Annual Enrollment Period presents a complex landscape with mixed financial implications for beneficiaries and industry stakeholders. Average monthly premiums for Medicare Advantage (MA) plans with prescription drug coverage are projected to decrease from $16 in 2025 to $14 in 2026, while stand-alone Part D premiums are also set to drop from $38 to $34. However, the number of stand-alone Part D plans will decline significantly from 464 to 360, and some MA providers, including UnitedHealthcare (UNH), are reducing service areas or coverage options, indicating potential consolidation and reduced choice.

CMS drug price negotiations are expected to yield substantial discounts, ranging from 38% to 79%, on list prices for 10 widely used prescriptions, including key blood thinners and diabetes medications. This development poses a significant headwind for pharmaceutical companies such as Bristol Myers Squibb (BMY), Pfizer (PFE), and Johnson & Johnson (JNJ), as reflected in their negative per-ticker sentiment scores. Concurrently, while the annual out-of-pocket limit for MA in-network services will slightly decrease to $9,250, the annual cap for Part D drugs will increase from $2,000 to $2,100, potentially shifting cost burdens to beneficiaries for high-cost medications.

Despite overall premium reductions, insurers will gain increased flexibility to raise Part D premiums by up to $50 per month, compared to the previous $35 maximum, which could lead to higher costs for some beneficiaries, particularly for specialty medications. The decision not to cover GLP-1 weight-loss drugs for obesity, while still covering them for diabetes, creates a nuanced market for pharmaceutical firms like Novo Nordisk (NVO). Furthermore, potential government shutdowns pose risks of delayed claims processing and reduced telehealth services, impacting healthcare providers and patient access.

Key Decisions for Investors

• Investors in health insurance providers should monitor the impact of reduced service areas and the new flexibility in Part D premium adjustments on profitability and market share, especially given the overall premium decreases.
• Pharmaceutical investors should assess the financial implications of CMS drug price negotiations and the specific coverage limitations for GLP-1 drugs, which could significantly impact revenue streams for affected medications from companies like BMY, PFE, JNJ, LLY, and NVO.
• Consider the potential for increased demand for plan comparison tools and services from platforms like eHealth (EHTH) due to the complexity of mixed premium changes, plan reductions, and new enrollment periods.
• Evaluate the risks associated with potential government shutdowns, including delayed payments to healthcare providers and reduced telehealth services, which could affect operational cash flow and patient engagement across the healthcare sector.